TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical
technology company focused on designing, developing, and marketing
innovative tissue reinforcement materials to address unmet needs in
soft tissue reconstruction, today announced three upcoming poster
presentations on its OviTex Reinforced Tissue Matrix portfolio.
Data demonstrating the effectiveness of OviTex in a variety of
hernia repairs will be presented at the Society of American
Gastrointestinal and Endoscopic Surgeons (SAGES) conference from
August 31 through September 3, 2021 in Las Vegas, Nevada.
"We are thankful to the surgeons who have followed their
patients' outcomes and are presenting at SAGES. Hernia repair is a
challenging problem, but data such as the research on our OviTex
portfolio to be presented at SAGES demonstrates that when you
meaningfully collaborate with surgeons, you can solve problems and
improve outcomes," said Antony Koblish, CEO of TELA Bio. "Our
unique platform allowed us to build a portfolio of products which
can be utilized through multiple surgical techniques to help repair
a variety of hernia types. In addition, our flexible platform and
dedication to incorporating surgeon feedback are essential in
developing innovative solutions for soft tissue
reconstruction."
Designed by leading experts, with collaboration from more than
100 surgeons, OviTex Reinforced Tissue Matrix is an advanced hernia
repair technology that utilizes naturally sourced tissue reinforced
with interwoven polymer fibers to facilitate tissue remodeling
while optimizing strength and minimizing the foreign body
inflammatory response. This comprehensive portfolio is designed to
address multiple hernia types and enables surgeons to select the
implant best suited for the patient's specific needs.
"Dr. Banaschak and I are excited that SAGES has recognized our
work and look forward to sharing our positive results with OviTex,"
said Paul Szotek, MD, Medical Director of the Indiana Hernia
Center. "I began utilizing OviTex in my practice in 2016 with the
interest of reducing the amount of permanent synthetic polymer
exposure for my patients. Over the last five years, we've optimized
our results by leveraging OviTex's unique design along with proven
surgical techniques to develop what we refer to as the Reinforced
Biologic Augmented Repair or ReBAR."
"I'm pleased to be sharing the results of my use of OviTex in a
series of patients requiring bridged hernia repairs at SAGES," said
George DeNoto III, MD, FACS, director of General Surgery St.
Francis Hospital in New York. "These patients represent some of the
most challenging patients that we encounter as general surgeons,
and these data are very promising."
Poster presentations include:1. A Reinforced
Biologic Augmented Repair (ReBAR) of Coexisting Inguinal and
Incisional Hernias, 619 Patients, with Robotic Assistance (Cory
Banaschak, M.D. and Paul Szotek, MD, MBA, FACS);
2. Robotic-Assisted ReBAR of 111 Inguinal Hernias (Cory
Banaschak, MD and Paul Szotek, M.D., MBA, FACS); and
3. Use of Ovine Reinforced Tissue Matrix in Bridged Incisional
Hernia Repair (George DeNoto III, MD, FACS).
For the event's full agenda, visit:
https://www.sages2021.surgery/schedule-at-a-glance/
About TELA Bio, Inc.TELA Bio Inc. (NASDAQ:
TELA) is a commercial-stage medical technology company focused on
designing, developing, and marketing innovative tissue
reinforcement materials to address unmet needs in soft tissue
reconstruction. The company is committed to providing patients with
advanced, economically effective biologic material repair solutions
to minimize long-term exposure to permanent synthetic materials and
improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS
Reinforced Tissue Matrix products are purposefully designed to
address the shortcomings of existing reinforcement materials in
hernia repair, abdominal wall reconstruction and plastic and
reconstructive surgery. For more information, visit
www.telabio.com.
About OviTexOviTex Reinforced Tissue Matrix is
intended for use as a surgical mesh to reinforce and/or repair soft
tissue where weakness exists. Indications for use include the
repair of hernias and/or abdominal wall defects that require the
use of reinforcing or bridging material to obtain the desired
surgical outcome. Do not use OviTex in patients known to be
sensitive to materials of ovine (sheep) origin. For prescription
use only. For additional important safety information, please see
the OviTex Reinforced BioScaffold Instructions for Use.The
statements made or results achieved by TELA Bio customers described
herein were achieved in their specific setting. Due to variations
in clinical experience and technique, there is no guarantee that
these results are typical. A surgeon must use his or her own
clinical judgment when deciding which products are appropriate for
treatment of a particular patient. Always refer to the package
insert, product label, and/or instructions for use before using any
TELA Bio product. Products may not be available in all markets
because product availability is subject to the regulatory and/or
medical practices in individual markets
Caution Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations are forward-looking statements and reflect the current
beliefs of TELA's management. These statements are not guarantees
of future performance and are subject to certain risks,
uncertainties and other factors that could cause actual results and
events to differ materially and adversely from those indicated by
such forward-looking statements including, among others, the impact
to our business of the ongoing COVID-19 pandemic and the
development of new variants of COVID-19, such as the delta variant,
including but not limited to any impact on our ability to market
our products, demand for our products due to deferral of procedures
using our products or disruption in our supply chain, our ability
to achieve or sustain profitability, our ability to gain market
acceptance for our products and to accurately forecast and meet
customer demand, our ability to compete successfully, our ability
to enhance our product offerings, our ability to enhance our
product offerings, development and manufacturing problems, capacity
constraints or delays in production of our products, maintenance of
coverage and adequate reimbursement for procedures using our
products, and product defects or failures. These and other risks
and uncertainties are described more fully in the "Risk Factors"
section and elsewhere in our filings with the Securities and
Exchange Commission and available at www.sec.gov, including in our
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any
forward-looking statements that we make in this announcement speak
only as of the date of this press release, and TELA assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise after the date of
this press release, except as required under applicable law.
Investor ContactGreg Chodaczek347-620-7010
ir@telabio.com
Media ContactAlyson
Kuritz908-892-7149alyson@0to5.com
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From Aug 2024 to Sep 2024
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From Sep 2023 to Sep 2024